NF2 and meningioma: An important caveat is that these classifiers may be insufficiently powered to include rare subsets of poor-performing NF2-wild-type tumors including meningiomas with BAP1 mutations, and management of these unusual, but clinically important cases should be carefully considered on an individual patient basis.